IBDEI095 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3735,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,3735,1,4,0)
 ;;=4^M79.1
 ;;^UTILITY(U,$J,358.3,3735,2)
 ;;=^5013321
 ;;^UTILITY(U,$J,358.3,3736,0)
 ;;=G72.1^^28^258^94
 ;;^UTILITY(U,$J,358.3,3736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3736,1,3,0)
 ;;=3^Myopathy,Alcoholic
 ;;^UTILITY(U,$J,358.3,3736,1,4,0)
 ;;=4^G72.1
 ;;^UTILITY(U,$J,358.3,3736,2)
 ;;=^5004096
 ;;^UTILITY(U,$J,358.3,3737,0)
 ;;=G72.81^^28^258^95
 ;;^UTILITY(U,$J,358.3,3737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3737,1,3,0)
 ;;=3^Myopathy,Critical Illness
 ;;^UTILITY(U,$J,358.3,3737,1,4,0)
 ;;=4^G72.81
 ;;^UTILITY(U,$J,358.3,3737,2)
 ;;=^328484
 ;;^UTILITY(U,$J,358.3,3738,0)
 ;;=G72.0^^28^258^96
 ;;^UTILITY(U,$J,358.3,3738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3738,1,3,0)
 ;;=3^Myopathy,Drug-Induced
 ;;^UTILITY(U,$J,358.3,3738,1,4,0)
 ;;=4^G72.0
 ;;^UTILITY(U,$J,358.3,3738,2)
 ;;=^5004095
 ;;^UTILITY(U,$J,358.3,3739,0)
 ;;=G72.41^^28^258^97
 ;;^UTILITY(U,$J,358.3,3739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3739,1,3,0)
 ;;=3^Myopathy,Inclusion Body Myositis
 ;;^UTILITY(U,$J,358.3,3739,1,4,0)
 ;;=4^G72.41
 ;;^UTILITY(U,$J,358.3,3739,2)
 ;;=^5004098
 ;;^UTILITY(U,$J,358.3,3740,0)
 ;;=G72.49^^28^258^98
 ;;^UTILITY(U,$J,358.3,3740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3740,1,3,0)
 ;;=3^Myopathy,Inflammatory/Immune NEC
 ;;^UTILITY(U,$J,358.3,3740,1,4,0)
 ;;=4^G72.49
 ;;^UTILITY(U,$J,358.3,3740,2)
 ;;=^5004099
 ;;^UTILITY(U,$J,358.3,3741,0)
 ;;=G72.2^^28^258^99
 ;;^UTILITY(U,$J,358.3,3741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3741,1,3,0)
 ;;=3^Myopathy,Other Toxic Agents
 ;;^UTILITY(U,$J,358.3,3741,1,4,0)
 ;;=4^G72.2
 ;;^UTILITY(U,$J,358.3,3741,2)
 ;;=^5004097
 ;;^UTILITY(U,$J,358.3,3742,0)
 ;;=G72.3^^28^258^100
 ;;^UTILITY(U,$J,358.3,3742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3742,1,3,0)
 ;;=3^Myopathy,Periodic Paralysis
 ;;^UTILITY(U,$J,358.3,3742,1,4,0)
 ;;=4^G72.3
 ;;^UTILITY(U,$J,358.3,3742,2)
 ;;=^335326
 ;;^UTILITY(U,$J,358.3,3743,0)
 ;;=G72.9^^28^258^101
 ;;^UTILITY(U,$J,358.3,3743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3743,1,3,0)
 ;;=3^Myopathy,Unspec
 ;;^UTILITY(U,$J,358.3,3743,1,4,0)
 ;;=4^G72.9
 ;;^UTILITY(U,$J,358.3,3743,2)
 ;;=^5004101
 ;;^UTILITY(U,$J,358.3,3744,0)
 ;;=M60.9^^28^258^102
 ;;^UTILITY(U,$J,358.3,3744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3744,1,3,0)
 ;;=3^Myositis,Unspec
 ;;^UTILITY(U,$J,358.3,3744,1,4,0)
 ;;=4^M60.9
 ;;^UTILITY(U,$J,358.3,3744,2)
 ;;=^5012409
 ;;^UTILITY(U,$J,358.3,3745,0)
 ;;=M79.2^^28^258^103
 ;;^UTILITY(U,$J,358.3,3745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3745,1,3,0)
 ;;=3^Neuralgia & Neuritis,Unspec
 ;;^UTILITY(U,$J,358.3,3745,1,4,0)
 ;;=4^M79.2
 ;;^UTILITY(U,$J,358.3,3745,2)
 ;;=^5013322
 ;;^UTILITY(U,$J,358.3,3746,0)
 ;;=M54.81^^28^258^104
 ;;^UTILITY(U,$J,358.3,3746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3746,1,3,0)
 ;;=3^Neuralgia,Occipital
 ;;^UTILITY(U,$J,358.3,3746,1,4,0)
 ;;=4^M54.81
 ;;^UTILITY(U,$J,358.3,3746,2)
 ;;=^5012312
 ;;^UTILITY(U,$J,358.3,3747,0)
 ;;=M89.70^^28^258^106
 ;;^UTILITY(U,$J,358.3,3747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3747,1,3,0)
 ;;=3^Osseous Defect,Major,Unspec Site
 ;;^UTILITY(U,$J,358.3,3747,1,4,0)
 ;;=4^M89.70
 ;;^UTILITY(U,$J,358.3,3747,2)
 ;;=^5015085
 ;;^UTILITY(U,$J,358.3,3748,0)
 ;;=M79.81^^28^258^105
 ;;^UTILITY(U,$J,358.3,3748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,3748,1,3,0)
 ;;=3^Nontraumatic Hematoma,Soft Tissue
 ;;^UTILITY(U,$J,358.3,3748,1,4,0)
 ;;=4^M79.81
 ;;^UTILITY(U,$J,358.3,3748,2)
 ;;=^5013356
